RESUMO
Research on the biology of fetal-maternal barriers has been limited by access to physiologically relevant cells, including trophoblast cells. In this study, we describe the development of a human term placenta-derived cytotrophoblast immortalized cell line (hPTCCTB) derived from the basal plate. Human-term placenta-derived cytotrophoblast immortalized cell line cells are comparable to their primary cells of origin in terms of morphology, marker expression, and functional responses. We demonstrate that these can transform into syncytiotrophoblast and extravillous trophoblasts. We also compared the hPTCCTB cells to immortalized chorionic trophoblasts (hFM-CTC), trophoblasts of the chorionic plate, and BeWo cells, choriocarcinoma cell lines of conventional use. Human-term placenta-derived cytotrophoblast immortalized cell line and hFM-CTCs displayed more similarity to each other than to BeWos, but these differ in syncytialization ability. Overall, this study (1) demonstrates that the immortalized hPTCCTB generated are cells of higher physiological relevance and (2) provides a look into the distinction between the spatially distinct placental and fetal barrier trophoblasts cells, hPTCCTB and hFM-CTC, respectively.
Assuntos
Placenta , Trofoblastos , Humanos , Trofoblastos/citologia , Trofoblastos/fisiologia , Feminino , Gravidez , Placenta/citologia , Placenta/fisiologia , Linhagem CelularAssuntos
Intoxicação por Tetracloreto de Carbono/complicações , Tetracloreto de Carbono/toxicidade , Adulto , Tetracloreto de Carbono/efeitos adversos , Tetracloreto de Carbono/história , Intoxicação por Tetracloreto de Carbono/etiologia , Serviço Hospitalar de Emergência/organização & administração , Sistemas de Combate a Incêndio/história , Hematemese/etiologia , História do Século XX , Humanos , Fígado/anormalidades , Fígado/efeitos dos fármacos , Fígado/fisiopatologia , Masculino , Vômito/tratamento farmacológico , Vômito/etiologiaRESUMO
OBJECTIVE: To evaluate the safety of the coadministration of selegiline with cold medications. DATA SOURCES: Clinical literature accessed through MEDLINE (1965 -September 2002), IPA database, and Drug-Reax System. The following search terms were used: selegiline, pseudoephedrine, dextromethorphan, MAOI, and drug interactions. Somerset Pharmaceuticals, the marketers of Eldepryl (selegiline HCl), were also contacted. DATA SYNTHESIS: Despite a warning against its concomitant use with pseudoephedrine and dextromethorphan, interactions with selegiline have not been reported. However, there have been reports of patients experiencing adverse events with related agents. CONCLUSIONS: Patients taking selegiline should try to avoid pseudoephedrine and dextromethorphan or use drugs without interaction potential. If selegiline is used with these medications, watch for adverse events or replace selegiline with another drug.
